NIH intends to publish a funding opportunity announcement (FOA) to solicit applications that develop and apply innovative synthetic biology approaches to address challenges across the continuum of cancer research.
This Notice is being provided to allow potential applicants time to develop responsive projects and meaningful collaborations.
The FOA is expected to be published in October 2020 with expected application due dates in January 2021.
The FOA will use the U01 activity code (Clinical Trial Not Allowed).
Details of the planned FOA are provided below.
The planned FOA intends to support synthetic biology approaches for cancer research that will expand technology development, promote transdisciplinary partnerships, and spur new efforts to advance mechanistic understanding of cancer and possibilities for cancer prevention, detection, and management. Projects will be required to define an important cancer research question and then approach that question with a synthetic biology technology, based on an adapted biological system that can sense an input, apply logic to determine a response to the input, and initiate a response. The emphasis is on both the significance of the cancer research question and the innovation and potential of the technical approach. Multi-PI applications are encouraged and transdisciplinary teams are expected with a requirement for expertise in cancer research and engineering or other disciplines relevant to synthetic biology.
Up to $4.2 million in fiscal year 2021
Application budgets are limited to $499,999 in direct costs per year and must reflect the actual needs of the proposed project.
93.286; 93.393; 93.394; 93.395;93.396; 93.399
Applications are not being solicited at this time.
Please direct all inquiries to:
Michelle Berny-Lang, PhD
National Cancer Institute (NCI)
David Rampulla, PhD
National Institute of Biomedical Imaging and Bioengineering (NIBIB)